Gene Expression and Pathway Analysis of Ovarian Cancer Cells Selected for Resistance to Cisplatin, Paclitaxel, or Doxorubicin

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2011 Dec 7

PMID 22141344

Citations 50

Authors

Cheryl A Sherman-Baust

Kevin G Becker

William H Wood Iii

Yongqing Zhang

Patrice J Morin

Affiliations

Soon will be listed here.

Abstract

Background: Resistance to current chemotherapeutic agents is a major cause of therapy failure in ovarian cancer patients, but the exact mechanisms leading to the development of drug resistance remain unclear.

Methods: To better understand mechanisms of drug resistance, and possibly identify novel targets for therapy, we generated a series of drug resistant ovarian cancer cell lines through repeated exposure to three chemotherapeutic drugs (cisplatin, doxorubicin, or paclitaxel), and identified changes in gene expression patterns using Illumina whole-genome expression microarrays. Validation of selected genes was performed by RT-PCR and immunoblotting. Pathway enrichment analysis using the KEGG, GO, and Reactome databases was performed to identify pathways that may be important in each drug resistance phenotype.

Results: A total of 845 genes (p < 0.01) were found altered in at least one drug resistance phenotype when compared to the parental, drug sensitive cell line. Focusing on each resistance phenotype individually, we identified 460, 366, and 337 genes significantly altered in cells resistant to cisplatin, doxorubicin, and paclitaxel, respectively. Of the 845 genes found altered, only 62 genes were simultaneously altered in all three resistance phenotypes. Using pathway analysis, we found many pathways enriched for each resistance phenotype, but some dominant pathways emerged. The dominant pathways included signaling from the cell surface and cell movement for cisplatin resistance, proteasome regulation and steroid biosynthesis for doxorubicin resistance, and control of translation and oxidative stress for paclitaxel resistance.

Conclusions: Ovarian cancer cells develop drug resistance through different pathways depending on the drug used in the generation of chemoresistance. A better understanding of these mechanisms may lead to the development of novel strategies to circumvent the problem of drug resistance.

Citing Articles

Transcriptomic Profiling of Carboplatin- and Paclitaxel-Resistant Lung Adenocarcinoma Cells Reveals as a Potential Biomarker for the Carboplatin Plus Paclitaxel Doublet Regimens.

Raungrut P, Tanyapattrapong S, Masjon T, Maungchanburi S, Thongsuksai P Curr Issues Mol Biol. 2024; 46(12):13951-13969.

PMID: 39727962 PMC: 11727171. DOI: 10.3390/cimb46120834.

α2β1 Integrin specific inhibitor BTT-3033 promotes paclitaxel-induced apoptosis in human ovarian cancer cells.

Babaei Z, Amani M, Minaiyan M, Ghorbanhosseini S, Aghaei M Res Pharm Sci. 2024; 19(5):549-560.

PMID: 39691300 PMC: 11648348. DOI: 10.4103/RPS.RPS_245_23.

Sex Differences in Ependymoma Methylation by Methylation-Defined Subgroup.

Mestnik S, Sorajja N, Lu Z, Mills L, Williams L J Cell Mol Med. 2024; 28(24):e70286.

PMID: 39679838 PMC: 11647990. DOI: 10.1111/jcmm.70286.

LncRNAs in modulating cancer cell resistance to paclitaxel (PTX) therapy.

Alkhathami A, Pallathadka H, Shah S, Ganesan S, Sharma A, Devi S Med Oncol. 2024; 42(1):28.

PMID: 39671022 DOI: 10.1007/s12032-024-02577-1.

NF-kappa B signaling pathway is associated with metformin resistance in type 2 diabetes patients.

Mansouri V, Bandarian F, Razi F, Razzaghi Z, Rezaei-Tavirani M, Rezaei M J Diabetes Metab Disord. 2024; 23(2):2021-2030.

PMID: 39610517 PMC: 11599502. DOI: 10.1007/s40200-024-01458-8.

References

Agarwal R, Kaye S . Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003; 3(7):502-16. DOI: 10.1038/nrc1123. View

Ma M, Yang H, Parker K, Manyak S, Friedman J, Altamirano C . The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003; 9(3):1136-44. View

Cheadle C, Vawter M, Freed W, Becker K . Analysis of microarray data using Z score transformation. J Mol Diagn. 2003; 5(2):73-81. PMC: 1907322. DOI: 10.1016/S1525-1578(10)60455-2. View

Szakacs G, Paterson J, Ludwig J, Booth-Genthe C, Gottesman M . Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3):219-34. DOI: 10.1038/nrd1984. View

Ling Y, El-Naggar A, Priebe W, Perez-Soler R . Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol. 1996; 49(5):832-41. View

Cody N, Ouellet V, Manderson E, Quinn M, Filali-Mouhim A, Tellis P . Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Oncogene. 2006; 26(4):618-32. DOI: 10.1038/sj.onc.1209821. View

del Prete M, Robles M, Guao A, Martinez-A C, Izquierdo M, Garcia-Sanz J . Degradation of cellular mRNA is a general early apoptosis-induced event. FASEB J. 2002; 16(14):2003-5. DOI: 10.1096/fj.02-0392fje. View

Sherman-Baust C, Weeraratna A, Rangel L, Pizer E, Cho K, Schwartz D . Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell. 2003; 3(4):377-86. DOI: 10.1016/s1535-6108(03)00058-8. View

Wu H, Cao Y, Weng D, Xing H, Song X, Zhou J . Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Cancer Lett. 2008; 271(2):260-71. DOI: 10.1016/j.canlet.2008.06.012. View

10.

Chandra J, Samali A, Orrenius S . Triggering and modulation of apoptosis by oxidative stress. Free Radic Biol Med. 2000; 29(3-4):323-33. DOI: 10.1016/s0891-5849(00)00302-6. View

11.

Li J, Sherman-Baust C, Tsai-Turton M, Bristow R, Roden R, Morin P . Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer. 2009; 9:244. PMC: 2719664. DOI: 10.1186/1471-2407-9-244. View

12.

Garde S, Basrur V, Li L, Finkelman M, Krishan A, WELLHAM L . Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. Prostate. 1999; 38(2):118-25. DOI: 10.1002/(sici)1097-0045(19990201)38:2<118::aid-pros5>3.0.co;2-g. View

13.

Sethi T, Rintoul R, Moore S, Mackinnon A, Salter D, Choo C . Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med. 1999; 5(6):662-8. DOI: 10.1038/9511. View

14.

Shukeir N, Garde S, Wu J, Panchal C, Rabbani S . Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer. Anticancer Drugs. 2005; 16(10):1045-51. DOI: 10.1097/00001813-200511000-00002. View

15.

McGuire W, Hoskins W, Brady M, Kucera P, Partridge E, Look K . Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996; 334(1):1-6. DOI: 10.1056/NEJM199601043340101. View

16.

Shukeir N, Arakelian A, Chen G, Garde S, Ruiz M, Panchal C . A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia. Cancer Res. 2004; 64(15):5370-7. DOI: 10.1158/0008-5472.CAN-04-0788. View

17.

Gleichmann M, Zhang Y, Wood 3rd W, Becker K, Mughal M, Pazin M . Molecular changes in brain aging and Alzheimer's disease are mirrored in experimentally silenced cortical neuron networks. Neurobiol Aging. 2010; 33(1):205.e1-18. PMC: 3027841. DOI: 10.1016/j.neurobiolaging.2010.08.012. View

18.

Ishida S, Lee J, Thiele D, Herskowitz I . Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002; 99(22):14298-302. PMC: 137878. DOI: 10.1073/pnas.162491399. View

19.

Siegel R, Ward E, Brawley O, Jemal A . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-36. DOI: 10.3322/caac.20121. View

20.

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View